Skip to content
Screener

Harrow HROW Total Equity

Total Equity at other companies

AbbVie logo
AbbVieABBV
-$6.66B-569%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$30.62M+25.2%
Bausch + Lomb logo
Bausch + LombBLCO
$6.38B-1.0%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$581.57M+119%
Opko Health logo
Opko HealthOPK
$1.18B-8.7%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$2.06B-74.0%

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.49B+22.8%
Enterprise value$1.7B+5.6%
P/S5.5×+0.2×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Harrow’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001493152-26-022254
Line itemMarch 31, 2026December 31, 2025
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 37,269,400 and 37,229,159 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively37,00037,000
Additional paid-in capital212,795,000208,933,000
Accumulated deficit(184,126,000)(156,524,000)
TOTAL HARROW, INC. STOCKHOLDERS’ EQUITY28,706,00052,446,000
Noncontrolling interests(355,000)(355,000)
TOTAL STOCKHOLDERS’ EQUITY28,351,00052,091,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$419,543,000$399,482,000

Item 1. Financial Statements (unaudited) Item

FAQ

What is Harrow's total equity?
Harrow (HROW) reported total equity of $28.71M in Q1 2026.
How has Harrow's total equity changed year-over-year?
Harrow's total equity decreased by 49.1% year-over-year, from $56.45M to $28.71M.
What is the long-term trend for Harrow's total equity?
Over 5 years (2020 to 2025), Harrow's total equity has grown at a 14.0% compound annual growth rate (CAGR), from $27.18M to $52.45M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Harrow's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude